A cultural divide exists in biotech investing. East Coast VCs, rooted in a traditional biotech ecosystem, are more skeptical of AI and demand hard biological data. West Coast VCs, surrounded by tech innovation, are more comfortable backing the promise of AI platforms before seeing extensive wet lab validation.

While lacking investor density, cities like Houston thrive by tapping into world-class academic medical centers (e.g., MD Anderson) for talent and collaborations. Furthermore, significant state-level funding, like Texas's CPRIT, can bridge the early-stage capital gap often filled by local VCs in major hubs.

Iterion CEO Rahul Aras argues that being outside a major biotech hub is a real fundraising hurdle. The issue isn't overt investor bias, but rather the loss of natural networking opportunities—like bumping into investors at a local coffee shop—that are common in dense ecosystems and must be overcome with proactive outreach.

Historically, the French biotech scene was held back by a lack of large domestic investment funds. This has changed significantly, with local VCs now raising large funds capable of leading nine-figure rounds. This growing financial muscle allows French biotechs to scale effectively within their own ecosystem.

The biotech venture model is built on syndication, not competition. As a drug progresses, capital requirements balloon to hundreds of millions for late-stage trials, far exceeding any single VC's capacity. This structural reality forces firms to co-invest and partner throughout a company's lifecycle.

Repro Novo's co-founders invested their own money for the costly process of finding and negotiating assets. This allowed them to secure a promising candidate before approaching institutional investors, demonstrating strong conviction and de-risking the initial investment for VCs.

A profound capital shift has occurred where both venture investors and large pharma partners focus on clinically validated assets. This moves investment away from riskier, early-stage science, creating a significant funding gap for foundational research and pre-clinical startups.

Europe's strong science is often held back by a lack of serial entrepreneurs, difficulty in raising follow-on funding, and a localized competitive view. Curie.Bio’s model directly counters these issues by providing an experienced drug-making team, a clear funding path, and an embedded global market perspective.

A massive, multi-trillion dollar wealth transfer is making family offices more institutionalized and eager to diversify into alternative investments like life sciences. Luba Greenwood points to this as a significant, often overlooked fundraising channel for biotech companies seeking direct investment.